The numbers behind
telehealth and hormones.
Every figure is taken from a government agency, a peer-reviewed study or a company filing, and links to the page it came from. Free to cite with a link.
US pharmacies specialize in compounding, according to an American Pharmacists Association estimate (2020)
29 figures → Direct-to-consumer telehealth statistics $2,347.6 millionHims & Hers revenue in 2025, up 59% year over year
31 figures → Erectile dysfunction statistics 30 million to 50 millionmen in the United States have erectile dysfunction
28 figures → GLP-1 statistics 18%of US adults say they have ever taken a GLP-1 drug for weight loss, diabetes or another condition
32 figures → Hair loss statistics 50 millionmen in the United States are estimated to have androgenetic alopecia (male pattern hair loss)
30 figures → Hormone replacement therapy statistics 90 millionannual US hormone therapy prescriptions in 1999, up from 58 million in 1995
29 figures → Longevity and biomarker testing statistics $3.91 billionis the projected size of the US direct-to-consumer laboratory testing market by 2032
34 figures → Low testosterone statistics 38.7%of men aged 45 and older visiting US primary care practices had hypogonadism, defined as total testosterone below 300 ng/dL
27 figures → Men's health statistics 76.5 yearslife expectancy at birth for US males in 2024, up 0.7 year from 75.8 years in 2023
33 figures → Menopause statistics 52is the average age at menopause in the United States
28 figures → Obesity statistics 40.3%of US adults age 20 and older had obesity (BMI 30 or higher) in August 2021 to August 2023
34 figures → Peptide statistics More than 80peptide drugs have reached the market since the introduction of insulin almost a century ago
29 figures → Prediabetes and insulin resistance statistics 115.2 millionUS adults aged 18 and older are estimated to have prediabetes
34 figures → SARMs statistics 1% to 3%of athletes are estimated to use SARMs
29 figures → Semaglutide statistics 2 millionMedicare Part D enrollees took Ozempic in 2024, up from fewer than 150,000 in 2019
33 figures → Sleep and insomnia statistics 30.5%of US adults slept less than 7 hours in a 24-hour period on average in 2024
35 figures → Telehealth statistics 37.0%of US adults used telemedicine in the past 12 months in 2021
30 figures → Tirzepatide statistics nearly 1 millionMedicare Part D enrollees took Mounjaro in 2024, up from 54,000 in 2022
33 figures → TRT statistics 0.93%of male patients had an active testosterone prescription in 2025
34 figures → Weight loss drug cost statistics $1,349.02list price (WAC) of a four-pen package of Wegovy injection, the same for every dose
30 figures →How these pages are made
Each page is researched from primary sources: CDC and NIH data, FDA records, peer-reviewed studies, and company filings. Figures are reported exactly as the source states them, with the year the data refers to. Pages are dated and updated as new data is published. See our editorial standards.
Sources
Regulatory and primary sources
- 360Dx: Coverage of Quest Diagnostics fourth-quarter 2025 earnings call ↗ · 2026
- AJMC (American Journal of Managed Care): FDA panel backs 6 peptides for compounding ↗ · 2026
- AJPM Focus: Prediabetes Awareness Barriers and Enablers: National Health and Nutrition Examination Survey 2011-2020 (Wang et al.) ↗ · 2025
- Alimentary Pharmacology & Therapeutics: Drug-induced liver injury from selective androgen receptor modulators, anabolic-androgenic steroids and bodybuilding supplements in Australia (Nash et al.) ↗ · 2024
- Alliance for Pharmacy Compounding: A Snapshot of Pharmacy Compounding in America 2025-2026 ↗ · 2025
- American Cancer Society: Key Statistics for Prostate Cancer ↗ · 2026
- American Journal of Epidemiology: Factors related to age at natural menopause: longitudinal analyses from SWAN (Gold EB et al.) ↗ · 2013
- American Journal of Medicine: Prevalence and risk factors for erectile dysfunction in the US (Selvin E et al.) ↗ · 2007
- American Journal of Sports Medicine: Athlete Selective Androgen Receptor Modulators Abuse: A Systematic Review (Vasireddi et al.) ↗ · 2025
- Analytical and Bioanalytical Chemistry: Investigations into the elimination profiles and metabolite ratios of micro-dosed selective androgen receptor modulator LGD-4033 for doping control purposes (Wagener et al.) ↗ · 2022
- Andrology: First-generation phosphodiesterase type 5 inhibitors dropout: a comprehensive review and meta-analysis (Corona G et al.) ↗ · 2016
- Annals of Epidemiology: Testosterone prescribing in men with depression and anxiety disorders (Javed et al.) ↗ · 2020
- Annals of Internal Medicine: Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians ↗ · 2016
- Annals of Internal Medicine: Cognitive Behavioral Therapy for Chronic Insomnia: A Systematic Review and Meta-analysis (Trauer et al.) ↗ · 2015
- Archives of Internal Medicine: Treatment of symptomatic androgen deficiency: results from the Boston Area Community Health Survey (Hall et al.) ↗ · 2008
- Athletech News: Function Health Raises $298 Million at $2.5 Billion Valuation ↗ · 2025
- Behavioral Sleep Medicine: Estimating Public Knowledge About Cognitive Behavioral Therapy for Insomnia (CBT-I) and Alternative Treatments (Assar et al.) ↗ · 2026
- Biological Psychiatry: Prevalence and perceived health associated with insomnia based on DSM-IV-TR; ICD-10; and RDC/ICSD-2 criteria: results from the America Insomnia Survey (Roth et al.) ↗ · 2011
- BJU International: The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences (Ayta IA et al.) ↗ · 1999
- BJU International: The global prevalence of erectile dysfunction: a review (Kessler A et al.) ↗ · 2019
- British Journal of Dermatology: Hair density, hair diameter and the prevalence of female pattern hair loss (Birch MP et al.) ↗ · 2001
- CDC Morbidity and Mortality Weekly Report: Prevalence of Healthy Sleep Duration among Adults, United States, 2014 ↗ · 2016
- CDC National Center for Health Statistics: Mortality in the United States, 2024 (NCHS Data Brief No. 548) ↗ · 2026
- CDC National Center for Health Statistics: Mortality in the United States, 2023 (NCHS Data Brief No. 521) ↗ · 2024
- CDC National Center for Health Statistics: FastStats: Men's Health ↗ · 2026
- CDC National Center for Health Statistics: NHIS Adult Summary Health Statistics (National Health Interview Survey, 2025 estimates) ↗ · 2026
- CDC National Center for Health Statistics: Obesity and Severe Obesity Prevalence in Adults: United States, August 2021-August 2023 (NCHS Data Brief No. 508) ↗ · 2024
- CDC National Center for Health Statistics: Suicide Mortality in the United States, 2002-2022 (NCHS Data Brief No. 509) ↗ · 2024
- CDC National Center for Health Statistics: Mental Health Treatment Among Adults Aged 18-44: United States, 2019-2021 (NCHS Data Brief No. 444) ↗ · 2022
- CDC National Center for Health Statistics: Prevalence of Overweight, Obesity, and Severe Obesity Among Adults Age 20 and Older: United States, 1960–1962 Through August 2021–August 2023 (Health E-Stat 111) ↗ · 2026
- CDC National Center for Health Statistics: Prevalence of Overweight, Obesity, and Severe Obesity Among Children and Adolescents Ages 2–19 Years: United States, 1963–1965 Through August 2021–August 2023 (Health E-Stat 112) ↗ · 2026
- CDC National Center for Health Statistics: Telemedicine Use Among Adults: United States, 2021 (NCHS Data Brief No. 445) ↗ · 2022
- Centers for Disease Control and Prevention: Adult Obesity Facts ↗ · 2024
- Centers for Disease Control and Prevention: 2025 Adult Obesity Prevalence by State (BRFSS data table) ↗ · 2026
- Centers for Disease Control and Prevention: Adult Obesity Prevalence Maps (2025 BRFSS data) ↗ · 2026
- Centers for Disease Control and Prevention: Childhood Obesity Facts ↗ · 2024
- Centers for Disease Control and Prevention: National Diabetes Statistics Report ↗ · 2026
- Centers for Disease Control and Prevention: Prediabetes: Your Chance to Prevent Type 2 Diabetes ↗ · 2026
- Centers for Disease Control and Prevention: National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States (2024 edition, archived) ↗ · 2024
- Centers for Disease Control and Prevention: FastStats: Sleep in Adults ↗ · 2024
- Centers for Disease Control and Prevention: About Sleep ↗ · 2024
- Centers for Medicare & Medicaid Services: Medicare Telehealth Trends (data through Q1 2026) ↗ · 2026
- Centers for Medicare & Medicaid Services: Telehealth FAQ (updated October 2026) ↗ · 2026
- Centers for Medicare & Medicaid Services: Medicare Part D Spending by Drug (data year 2024) ↗ · 2026
- Circulation: Cardiovascular Quality and Outcomes: Prediction of cardiovascular events and all-cause mortality with erectile dysfunction: a systematic review and meta-analysis of cohort studies (Vlachopoulos CV et al.) ↗ · 2013
- Cleveland Clinic: Cleveland Clinic Survey: Men Will Do Almost Anything to Avoid Going to the Doctor ↗ · 2019
- ClinCalc DrugStats Database (based on AHRQ Medical Expenditure Panel Survey): Sildenafil - Drug Usage Statistics, United States, 2014 - 2024 ↗ · 2026
- ClinCalc DrugStats Database (based on AHRQ Medical Expenditure Panel Survey): Tadalafil - Drug Usage Statistics, United States, 2014 - 2024 ↗ · 2026
- ClinCalc DrugStats Database (based on AHRQ Medical Expenditure Panel Survey): Finasteride - Drug Usage Statistics, United States, 2014 - 2024 ↗ · 2026
- ClinCalc DrugStats Database (based on AHRQ Medical Expenditure Panel Survey): Estradiol - Drug Usage Statistics, United States, 2014 - 2024 ↗ · 2026
- Dermatologic Surgery: Prevalence of male pattern hair loss in 18-49 year old men (Rhodes T et al.) ↗ · 1998
- Diabetes Care: Testosterone concentrations in diabetic and nondiabetic obese men (Dhindsa et al.) ↗ · 2010
- Diabetes, Obesity and Metabolism: Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension ↗ · 2022
- Drug Enforcement Administration (Federal Register): Special Registrations for Telemedicine and Limited State Telemedicine Registrations (proposed rule) ↗ · 2025
- Drug Enforcement Administration and HHS (Federal Register): Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications ↗ · 2025
- Drug Enforcement Administration and HHS (Federal Register): Expansion of Buprenorphine Treatment via Telemedicine Encounter (final rule) ↗ · 2025
- Drug Enforcement Administration and HHS (Federal Register): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients (delay of effective date) ↗ · 2025
- Eli Lilly and Company: Lilly lowers the price of Zepbound (tirzepatide) single-dose vials ↗ · 2025
- Eli Lilly and Company: LillyDirect: Zepbound ↗ · 2026
- Eli Lilly and Company (Form 10-K, SEC): Annual report for the fiscal year ended December 31, 2025 ↗ · 2026
- Eli Lilly and Company (Form 8-K, SEC): Lilly reports second-quarter 2026 financial results ↗ · 2026
- Eli Lilly and Company (SEC Form 8-K, Exhibit 99.1): Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance ↗ · 2026
- Eli Lilly and Company (via BioSpace): Foundayo (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.S. ↗ · 2026
- Epic Research: Hormone Therapy Use Nearly Doubled Since 2017, Led by Women in Their Late 40s and Early 50s ↗ · 2026
- Epic Research: After a Nearly Decade-Long Decrease, Testosterone Prescribing Rates Are Rising Again ↗ · 2026
- European Urology: Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease (Montorsi F et al.) ↗ · 2003
- European Urology Focus: Head-to-head Comparison of the Safety and Efficacy Profiles of Three Phosphodiesterase Type 5 Inhibitors through Patient-reported Outcomes of 130 000 Patients from a Direct-to-consumer Platform Database (Rodler S et al.) ↗ · 2026
- European Urology Focus: Decline in Serum Testosterone Levels Among Adolescent and Young Adult Men in the USA (Lokeshwar et al.) ↗ · 2021
- FDA Center for Drug Evaluation and Research: Office of Compliance Annual Report 2025 ↗ · 2026
- Federal Register (FDA notice, Docket No. FDA-2025-N-6895): Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments ↗ · 2026
- Femtech Insider: Midi Health Expands Beyond Menopause Care With New Brand Identity ↗ · 2026
- Fierce Healthcare: Oura raises $900M series E as smart ring sales catapult company's growth ↗ · 2025
- Frontiers in Endocrinology: Association between life's essential 8 and testosterone deficiency in US men: NHANES 2011-2016 (Mei et al.) ↗ · 2024
- Frontiers in Public Health: Prediabetes prevalence and awareness by race, ethnicity, and educational attainment among U.S. adults (Formagini et al.) ↗ · 2023
- Frontiers in Sleep: Examining the barriers and recommendations for integrating more equitable insomnia treatment options in primary care (Vargas et al.) ↗ · 2023
- Function Health: Function Health membership page ↗ · 2026
- Gallup: Obesity Rate Declining in U.S. ↗ · 2025
- Gallup: Five Aspects of Wellbeing Linked to GLP-1 Effectiveness ↗ · 2026
- HHS Office of Inspector General: Telehealth Was Critical for Providing Services to Medicare Beneficiaries During the First Year of the COVID-19 Pandemic (OEI-02-20-00520) ↗ · 2022
- Hims & Hers Health, Inc.: Hims Launches New Category in Men's Health with Exclusive Branded Oral Testosterone and Expanded Personalized Treatments ↗ · 2025
- Hims & Hers Health, Inc. (SEC Form 10-K): Annual Report for fiscal year 2025 ↗ · 2026
- Hims & Hers Health, Inc. (SEC Form 8-K, Exhibit 99.1): Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results ↗ · 2026
- Hims & Hers Health, Inc. (SEC Form 8-K, Exhibit 99.1): Hims & Hers Health, Inc. Reports Second Quarter 2026 Financial Results ↗ · 2026
- Hims & Hers Health, Inc. (SEC Form 8-K, Exhibit 99.1): Hims & Hers Health, Inc. Reports First Quarter 2026 Financial Results ↗ · 2026
- Hims & Hers Health, Inc. (SEC Form 8-K): Q4 2025 Shareholder Letter ↗ · 2026
- HSS Journal: Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review (Vasireddi et al.) ↗ · 2025
- Inquiry (University of Michigan National Poll on Healthy Aging data): Use of At-Home Medical Tests Among Older US Adults: A Nationally Representative Survey (Rager et al.) ↗ · 2024
- International Journal of Clinical Practice: Prevalence of hypogonadism in males aged at least 45 years: the HIM study (Mulligan et al.) ↗ · 2006
- International Journal of Impotence Research: Adverse effects and potential benefits among selective androgen receptor modulators users: a cross-sectional survey (Efimenko et al.) ↗ · 2022
- International Society of Hair Restoration Surgery: ISHRS 2022 Practice Census Results ↗ · 2022
- International Society of Hair Restoration Surgery: Worldwide Hair Restoration Trends (2025 Practice Census) ↗ · 2025
- International Society of Hair Restoration Surgery (via PR Newswire): New Survey Finds Younger Adults, More Women Seeking Treatment for Hair Loss ↗ · 2025
- ISPOR (IQVIA National Prescription Audit data): Assessing Prescribing Trends for Select GLP-1s by Patient Demographics, Providers, and Indication ↗ · 2025
- JAMA: Erectile dysfunction and subsequent cardiovascular disease (Thompson IM et al.) ↗ · 2005
- JAMA: Dispensing of Glucagon-Like Peptide-1 Receptor Agonists to Adolescents and Young Adults, 2020-2023 ↗ · 2024
- JAMA: National use of postmenopausal hormone therapy: annual trends and response to recent evidence (Hersh AL et al.) ↗ · 2004
- JAMA: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial (Rossouw JE et al.) ↗ · 2002
- JAMA: Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials (Manson JE et al.) ↗ · 2017
- JAMA: Chemical Composition and Labeling of Substances Marketed as Selective Androgen Receptor Modulators and Sold via the Internet (Van Wagoner et al.) ↗ · 2017
- JAMA: Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4) ↗ · 2021
- JAMA: Trends in Use of Melatonin Supplements Among US Adults, 1999-2018 (Li et al.) ↗ · 2022
- JAMA: Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4) ↗ · 2024
- JAMA: Testosterone Prescribing in the United States, 2002-2016 (Baillargeon et al.) ↗ · 2018
- JAMA Dermatology: Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride (Nguyen DD et al.) ↗ · 2021
- JAMA Health Forum: Postshortage Compounded GLP-1 RA Market in 2 States With Potentially High Demand (DiStefano et al.) ↗ · 2026
- JAMA Health Forum: Menopausal Hormone Therapy Use Among Postmenopausal Women (Yang L et al.) ↗ · 2024
- JAMA Internal Medicine: Trends in androgen prescribing in the United States, 2001 to 2011 (Baillargeon et al.) ↗ · 2013
- JAMA Internal Medicine: Duration of menopausal vasomotor symptoms over the menopause transition (Avis NE et al.) ↗ · 2015
- JAMA Internal Medicine: Guideline-Discordant Care Among Direct-to-Consumer Testosterone Therapy Platforms (Dubin et al.) ↗ · 2022
- JAMA Network Open: Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity ↗ · 2025
- JAMA Network Open: Changes in Minoxidil Prescribing After Media Attention About Oral Use for Hair Loss (Goodwin Cartwright BM et al.) ↗ · 2023
- JAMA Network Open: Use of Wearable Devices in Individuals With or at Risk for Cardiovascular Disease in the US, 2019 to 2020 (Dhingra et al.) ↗ · 2023
- JAMA Network Open: Stimulant, Antidepressant, and Opioid Telehealth Prescription Trends Between 2019 and 2022 (Nagappan et al.) ↗ · 2024
- JAMA Pediatrics: Prevalence of Prediabetes Among Adolescents and Young Adults in the United States, 2005-2016 (Andes et al.) ↗ · 2020
- JAMA Psychiatry: Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries (Jones et al.) ↗ · 2022
- JAMA Psychiatry: Association of Receipt of Opioid Use Disorder-Related Telehealth Services and Medications for Opioid Use Disorder With Fatal Drug Overdoses Among Medicare Beneficiaries (Jones et al.) ↗ · 2023
- JMIR Formative Research: Individual Perceptions of the Efficacy, Quality, and Safety of Sexual Health Care Delivered via a Direct-to-Consumer Telehealth Platform (Bohl M et al.) ↗ · 2026
- Journal of Clinical Endocrinology & Metabolism: Prevalence of symptomatic androgen deficiency in men (Araujo et al.) ↗ · 2007
- Journal of Clinical Endocrinology & Metabolism: Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging (Harman et al.) ↗ · 2001
- Journal of Clinical Endocrinology & Metabolism: Harmonized Reference Ranges for Circulating Testosterone Levels in Men of Four Cohort Studies in the United States and Europe (Travison et al.) ↗ · 2017
- Journal of Clinical Endocrinology & Metabolism: Characteristics of secondary, primary, and compensated hypogonadism in aging men: evidence from the European Male Ageing Study (Tajar et al.) ↗ · 2010
- Journal of Clinical Endocrinology & Metabolism: Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes (Dhindsa et al.) ↗ · 2004
- Journal of Clinical Endocrinology & Metabolism: Correlates of low testosterone and symptomatic androgen deficiency in a population-based sample (Hall et al.) ↗ · 2008
- Journal of Clinical Endocrinology & Metabolism: Insulin Resistance and Cardiometabolic Risk Profile Among Nondiabetic American Young Adults: Insights From NHANES (Parcha et al.) ↗ · 2022
- Journal of Clinical Endocrinology & Metabolism: Testosterone lab testing and initiation in the United Kingdom and the United States, 2000 to 2011 (Layton et al.) ↗ · 2014
- Journal of Clinical Medicine: Trends in Hyperinsulinemia and Insulin Resistance Among Nondiabetic US Adults, NHANES, 1999-2018 (Wu et al.) ↗ · 2025
- Journal of Drugs in Dermatology: Survey of Dermatology Practitioners' Opinions and Prescribing Habits of Oral Minoxidil for the Treatment of Androgenetic Alopecia (Sanfilippo E, Friedman A) ↗ · 2024
- Journal of Investigative Dermatology Symposium Proceedings: Prevalence of male and female pattern hair loss in Maryborough (Gan DC, Sinclair RD) ↗ · 2005
- Journal of Managed Care & Specialty Pharmacy: All-cause health care resource utilization and costs among adults with alopecia areata: A retrospective claims database study in the United States (Mostaghimi A et al.) ↗ · 2022
- Journal of Medical Internet Research: Self-Reported Side Effects Associated With Selective Androgen Receptor Modulators: Social Media Data Analysis (Joshi et al.) ↗ · 2025
- Journal of Medical Internet Research: Patient Satisfaction With Telemedicine During the COVID-19 Pandemic: Retrospective Cohort Study (Ramaswamy et al.) ↗ · 2020
- Journal of Medical Toxicology: National Poison Center Trends in GLP-1 Receptor Agonist Exposures Following FDA Approval for Weight Loss (Miller et al.) ↗ · 2026
- Journal of Sexual Medicine: One patient out of four with newly diagnosed erectile dysfunction is a young man (Capogrosso P et al.) ↗ · 2013
- Journal of Sexual Medicine: Undertreatment of erectile dysfunction: claims analysis of 6.2 million patients (Frederick LR et al.) ↗ · 2014
- Journal of Sexual Medicine: Vulvar and vaginal atrophy in postmenopausal women: findings from the REVIVE survey (Kingsberg SA et al.) ↗ · 2013
- Journal of the American Academy of Dermatology: Finasteride in the treatment of men with androgenetic alopecia (Kaufman KD et al.) ↗ · 1998
- Journal of the American Academy of Dermatology: A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men (Olsen EA et al.) ↗ · 2002
- Journal of Urology: Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study (Feldman HA et al.) ↗ · 1994
- Journal of Urology: What Is a Normal Testosterone Level for Young Men? Rethinking the 300 ng/dL Cutoff for Testosterone Deficiency in Men 20-44 Years Old (Zhu et al.) ↗ · 2022
- Journal of Xenobiotics: Systematic Review of Safety of Selective Androgen Receptor Modulators in Healthy Adults: Implications for Recreational Users (Vignali et al.) ↗ · 2023
- KFF: Poll: 1 in 8 Adults Say They Are Currently Taking a GLP-1 Drug for Weight Loss, Diabetes or Another Condition ↗ · 2025
- KFF: KFF Health Tracking Poll: Prescription Drug Costs, Views on Trump Administration Actions, and GLP-1 Use ↗ · 2025
- KFF: Recent Trends in GLP-1 Use and Spending in Medicare ↗ · 2026
- KFF: Medicaid Coverage of and Spending on GLP-1s ↗ · 2026
- KFF: 2025 Employer Health Benefits Survey ↗ · 2025
- KFF: A New Use for Wegovy Opens the Door to Medicare Coverage for Millions of People with Obesity ↗ · 2024
- KFF: What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge ↗ · 2026
- LifeMD, Inc. (SEC Form 8-K, Exhibit 99.1): LifeMD Reports Second Quarter 2026 Results ↗ · 2026
- LifeMD, Inc. (SEC Form 8-K, Exhibit 99.1): LifeMD Reports Fourth Quarter and Full Year 2025 Results ↗ · 2026
- Maturitas: Real-world evaluation of treatment utilization by women experiencing vasomotor symptoms associated with menopause in the United States and Europe: Findings from the REALISE study (Kingsberg S et al.) ↗ · 2024
- Mayo Clinic Proceedings: A population-based, longitudinal study of erectile dysfunction and future coronary artery disease (Inman BA et al.) ↗ · 2009
- Mayo Clinic Proceedings: Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989 (Safavi KH et al.) ↗ · 1995
- Mayo Clinic Proceedings: United States Menopausal Hormone Therapy Usage Trends: An Observational Study (Faubion SS et al.) ↗ · 2026
- Mayo Clinic Proceedings: Menopause Management Knowledge in Postgraduate Family Medicine, Internal Medicine, and Obstetrics and Gynecology Residents: A Cross-Sectional Survey (Kling JM et al.) ↗ · 2019
- Mayo Clinic Proceedings: Impact of Menopause Symptoms on Women in the Workplace (Faubion SS et al.) ↗ · 2023
- Medicare.gov (CMS): Weight loss drugs ↗ · 2026
- MedlinePlus Genetics, US National Library of Medicine: Androgenetic alopecia ↗ · 2023
- Menopause: Impact of the severity of vasomotor symptoms on health status, resource use, and productivity (Whiteley J et al.) ↗ · 2013
- Menopause: Incremental direct and indirect costs of untreated vasomotor symptoms (Sarrel P et al.) ↗ · 2015
- Mercer: Employers and workers face affordability crunch as health insurance cost is expected to exceed $18,500 per employee in 2026 ↗ · 2025
- Meticulous Research: U.S. Direct-to-Consumer Laboratory Testing Market to Reach $3.91 Billion by 2032 ↗ · 2024
- National Academies of Sciences, Engineering, and Medicine: The Clinical Utility of Compounded Bioidentical Hormone Therapy: A Review of Safety, Effectiveness, and Use (Appendix E) ↗ · 2020
- National Cancer Institute (HINTS): HINTS Brief 53: Patterns and Predictors of Telehealth Use among US Adults in 2022 ↗ · 2024
- National Center for Health Statistics (CDC): Prevalence of Total, Diagnosed, and Undiagnosed Diabetes in Adults: United States, August 2021-August 2023 (NCHS Data Brief No. 516) ↗ · 2024
- National Center for Health Statistics (CDC): Short Sleep Duration and Sleep Difficulties Among Adults: United States, 2024 (NCHS Data Brief No. 559) ↗ · 2026
- National Center for Health Statistics (CDC): Sleep Difficulties in Adults: United States, 2020 (NCHS Data Brief No. 436) ↗ · 2022
- National Center for Health Statistics (CDC): Sleep Medication Use in Adults Aged 18 and Over: United States, 2020 (NCHS Data Brief No. 462) ↗ · 2023
- National Heart, Lung, and Blood Institute (NIH): Study reveals wearable device trends among U.S. adults ↗ · 2023
- National Institute of Diabetes and Digestive and Kidney Diseases (NIH): Definition & Facts for Erectile Dysfunction ↗ · 2024
- Nature Reviews Disease Primers: Insomnia disorder (Spiegelhalder et al.) ↗ · 2026
- Nature Reviews Drug Discovery: Trends in peptide drug discovery (Muttenthaler et al.) ↗ · 2021
- NBC News: FDA panel calls to loosen restrictions on testosterone replacement therapy ↗ · 2025
- New England Journal of Medicine: The decrease in breast-cancer incidence in 2003 in the United States (Ravdin PM et al.) ↗ · 2007
- New England Journal of Medicine: Identification of late-onset hypogonadism in middle-aged and elderly men (Wu et al.) ↗ · 2010
- New England Journal of Medicine: Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE, Lincoff et al.) ↗ · 2023
- New England Journal of Medicine: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin (Diabetes Prevention Program) ↗ · 2002
- New England Journal of Medicine: Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) ↗ · 2021
- New England Journal of Medicine: Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity ↗ · 2025
- New England Journal of Medicine: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) ↗ · 2023
- New England Journal of Medicine: Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) ↗ · 2024
- New England Journal of Medicine: Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) ↗ · 2022
- New England Journal of Medicine: Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5) ↗ · 2025
- New England Journal of Medicine: Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA) ↗ · 2024
- New England Journal of Medicine: Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2) ↗ · 2021
- New England Journal of Medicine: Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes (SURPASS-CVOT) ↗ · 2025
- New England Journal of Medicine: Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT) ↗ · 2025
- Novo Nordisk: Novo Nordisk's Wegovy pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America ↗ · 2026
- Novo Nordisk: Wegovy pricing information ↗ · 2026
- Novo Nordisk: Ozempic pricing information ↗ · 2026
- Novo Nordisk (Form 6-K, SEC): Financial report for the period 1 January 2025 to 30 June 2025 ↗ · 2025
- Novo Nordisk (Form 6-K, SEC): Financial report for the period 1 January 2026 to 30 June 2026 ↗ · 2026
- Novo Nordisk (PR Newswire): Novo Nordisk's Wegovy HD available now nationwide ↗ · 2026
- Novo Nordisk (PR Newswire): Novo Nordisk launches introductory self-pay offer for Wegovy and Ozempic for $199 per month ↗ · 2025
- Novo Nordisk A/S (SEC Form 6-K): Financial report for the period 1 January 2025 to 31 December 2025 ↗ · 2026
- Novo Nordisk US: Wegovy Medicare GLP-1 Bridge Access (press release) ↗ · 2026
- Office on Women's Health, US Department of Health and Human Services: Menopause basics ↗ · 2026
- Office on Women's Health, US Department of Health and Human Services: Menopause symptoms and relief ↗ · 2025
- Operation Supplement Safety (U.S. Department of Defense): SARMs: What's the Harm? ↗ · 2025
- Pediatric Diabetes: Trends in Prevalence of Insulin Resistance Among Nondiabetic/Nonprediabetic Adolescents, 1999-2020 (Zhao et al.) ↗ · 2025
- Pew Research Center: About one-in-five Americans use a smart watch or fitness tracker ↗ · 2020
- Pharmaceuticals (Basel): 2023 FDA TIDES (Peptides and Oligonucleotides) Harvest (Al Shaer et al.) ↗ · 2024
- Pharmaceuticals (Basel): 2024 FDA TIDES (Peptides and Oligonucleotides) Harvest (Al Musaimi et al.) ↗ · 2025
- Pharmaceuticals (Basel): 2025 FDA TIDES (Peptides and Oligonucleotides) Harvest (AlShaer et al.) ↗ · 2026
- Pharmacoepidemiology and Drug Safety: Association of eszopiclone, zaleplon, or zolpidem with complex sleep behaviors resulting in serious injuries, including death (Harbourt et al.) ↗ · 2020
- PLOS One: Cross-sectional analysis of national testosterone prescribing through prescription drug monitoring programs, 2018-2022 (Selinger and Thallapureddy) ↗ · 2024
- Poison Control (National Capital Poison Center): Are selective androgen receptor modulators (SARMs) safe? ↗ · 2026
- Preventing Chronic Disease (CDC): Prevalence and Geographic Patterns of Self-Reported Short Sleep Duration Among US Adults, 2020 (Pankowska et al.) ↗ · 2023
- Psychological Medicine: Major depression during and after the menopausal transition: Study of Women's Health Across the Nation (SWAN) (Bromberger JT et al.) ↗ · 2011
- Quest Diagnostics: Quest Diagnostics Reports Fourth Quarter and Full Year 2025 Financial Results ↗ · 2026
- ResearchAndMarkets via GlobeNewswire: U.S. Direct-To-Consumer Telehealth Services Market Trends Analysis Report 2024-2030 ↗ · 2024
- Reuters via Yahoo Finance: Novo Nordisk CEO flags 1.5 million US users of compounded GLP-1 drugs ↗ · 2026
- Sacra: Ro revenue, valuation and funding ↗ · 2025
- Siemens Healthineers / YouGov: Insights and Trends from a National Survey: Patient Testing in America ↗ · 2025
- Signal Transduction and Targeted Therapy: Therapeutic peptides: current applications and future directions (Wang et al.) ↗ · 2022
- Sleep: Insomnia and the performance of US workers: results from the America Insomnia Survey (Kessler et al.) ↗ · 2011
- Sleep: National use of prescription medications for insomnia: NHANES 1999-2010 (Bertisch et al.) ↗ · 2014
- Sleep Medicine Reviews: Epidemiology of insomnia: what we know and what we still need to learn (Ohayon) ↗ · 2002
- Spa Business (reporting McKinsey Future of Wellness survey): McKinsey's 2024 Future of Wellness survey shows the sector continues to grow ↗ · 2024
- StatPearls (NCBI Bookshelf): Insulin Resistance ↗ · 2023
- TechCrunch: Function Health closes $298M Series B at a $2.5B valuation, launches medical intelligence ↗ · 2025
- Teladoc Health, Inc. (SEC Form 8-K, Exhibit 99.1): Teladoc Health Reports Second Quarter 2026 Results ↗ · 2026
- Telemedicine and e-Health: Satisfaction with Telehealth Care in the United States: Cross-Sectional Survey (Spaulding et al.) ↗ · 2024
- The Lancet: Prediabetes: a high-risk state for diabetes development (Tabak et al.) ↗ · 2012
- The Lancet Diabetes & Endocrinology: Long-term effects of lifestyle intervention or metformin on diabetes development and microvascular complications over 15-year follow-up: the Diabetes Prevention Program Outcomes Study ↗ · 2015
- The White House: Fact Sheet: President Donald J. Trump Announces Major Developments in Bringing Most-Favored-Nation Pricing to American Patients ↗ · 2025
- The White House: Fact Sheet: President Donald J. Trump Launches TrumpRx.gov to Bring Lower Drug Prices to American Patients ↗ · 2026
- The White House: Fact Sheet: President Donald J. Trump Announces Lower Drug Prices for All 50 State Medicaid Programs ↗ · 2026
- Truveta Research: Estrogen-based hormone replacement therapy use is rising ↗ · 2026
- U.S. Army: Supplements can mean dangers to health, job ↗ · 2022
- U.S. Department of Health and Human Services: HHS & DEA Extend Telemedicine Flexibilities for Prescribing Controlled Medications Through 2026 ↗ · 2026
- U.S. Food and Drug Administration: Registered Outsourcing Facilities (updated as of 9/30/2026) ↗ · 2026
- U.S. Food and Drug Administration: Human Drug Compounding Laws ↗ · 2024
- U.S. Food and Drug Administration: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize ↗ · 2026
- U.S. Food and Drug Administration: FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List ↗ · 2026
- U.S. Food and Drug Administration: FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss ↗ · 2026
- U.S. Food and Drug Administration: FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s ↗ · 2026
- U.S. Food and Drug Administration: FDA Clears First Over-the-Counter Continuous Glucose Monitor ↗ · 2024
- U.S. Food and Drug Administration: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks ↗ · 2026
- U.S. Food and Drug Administration: FDA Warns of Use of Selective Androgen Receptor Modulators (SARMs) Among Teens, Young Adults ↗ · 2023
- U.S. Food and Drug Administration: Warning letter: Dynamic Health Group dba SARMS America (December 12, 2025) ↗ · 2025
- U.S. Food and Drug Administration: Certain bodybuilding products put consumers at risk for heart attack, stroke, serious liver damage and more ↗ · 2025
- U.S. Food and Drug Administration: FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight ↗ · 2024
- U.S. Food and Drug Administration: FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use ↗ · 2015
- U.S. Food and Drug Administration: FDA issues class-wide labeling changes for testosterone products ↗ · 2025
- UK Anti-Doping: Health risks and misinformation online: UK Anti-Doping survey exposes products 'not for human consumption' ↗ · 2026
- University of Manchester: Researchers unzip symptoms of the male menopause ↗ · 2010
- Urology Times: FDA reports increased demand, supply efforts for estradiol transdermal patches ↗ · 2026
- US Food and Drug Administration: FDA alerts health care providers, compounders and consumers of potential risks associated with compounded topical finasteride products ↗ · 2025
- US Food and Drug Administration: HHS Advances Women's Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy ↗ · 2025
- US Food and Drug Administration: FDA Approves Labeling Changes to Menopausal Hormone Therapy Products ↗ · 2026
- US Food and Drug Administration: FDA Approves Novel Drug to Treat Moderate to Severe Hot Flashes Caused by Menopause ↗ · 2023
- US Food and Drug Administration (Drugs@FDA): Drugs@FDA: Viagra, NDA 020895 ↗ · 1998
- US Food and Drug Administration (Drugs@FDA): Drugs@FDA: Cialis, NDA 021368 ↗ · 2003
- US Food and Drug Administration (Drugs@FDA): Drugs@FDA: Propecia, NDA 020788 ↗ · 1997
- WW International, Inc. (SEC Form 8-K, Exhibit 99.1): WW International Second Quarter 2026 Results ↗ · 2026